Skip to content
PeptideAI
Human RCTimmunegut healthinflammationskin

Lactoferrin

An iron-binding glycoprotein from milk and mucosal secretions that starves bacteria of iron, disrupts viral entry and tunes mucosal immunity - the most widely used oral immune peptide there is.

Also known as apolactoferrin, bovine lactoferrin, LF, bLF, talactoferrin

Human RCT — Randomised controlled trials in humans, but not an approved product for this use.

Many randomised human trials exist, with the strongest results in iron-deficiency anaemia in pregnancy and as an H. pylori eradication adjunct. The counterweight is the large ELFIN trial in preterm infants, which found no reduction in late-onset sepsis - so the antimicrobial claims do not automatically translate to clinical endpoints.

How it works

Bovine lactoferrin is a roughly 80 kDa glycoprotein of 689 residues with two iron-binding lobes; the apo (iron-free) form is the one with antimicrobial activity, because its iron avidity strips the metal from the environment bacteria need it in. Beyond iron sequestration, the cationic N-terminal region - which yields the antimicrobial peptide lactoferricin on pepsin digestion - binds directly to lipopolysaccharide and bacterial membranes, causing permeabilisation. It also binds heparan sulfate proteoglycans on host cells, which blocks the attachment step for several viruses including rotavirus and coronaviruses in vitro. Immunologically it modulates TLR4 signalling, reduces NF-kB-driven cytokine output in inflamed mucosa, supports secretory IgA and shapes gut microbiota composition. It also meaningfully influences systemic iron handling by suppressing hepcidin, which is why it is used for iron-deficiency anaemia in pregnancy in some countries.

Targets: Free iron sequestration, Lipopolysaccharide, Heparan sulfate proteoglycans, TLR4 / NF-kB, Hepcidin

Dosing

ProtocolDoseFrequencyRoute
General immune and gut protocolAway from food and away from iron supplements, since binding to dietary iron reduces the apo form's activity.200 mg – 400 mgonce or twice dailyoral
Higher-dose antimicrobial / iron protocolEmpty stomach, morning and evening.400 mg – 1000 mgtwice dailyoral
  • · 200-400 mg daily is the mainstream supplement range and where most human data sit.
  • · Trials in iron-deficiency anaemia in pregnancy used around 100-200 mg twice daily; H. pylori adjunct protocols have used up to 200-400 mg twice daily. Doses above 1 g/day add cost and GI upset more than benefit.

Titration

Start at 200 mg once daily. Higher doses on an empty stomach are the main cause of the nausea people report.

Cycling

Safe to run continuously; most people use it during infection seasons or as an 8-12 week gut protocol rather than indefinitely.

Work out your exact syringe units →

Pharmacology

Half-life
Orally, most of it acts locally in the gut rather than entering circulation; intravenously administered lactoferrin clears within hours.
Onset
Gut and mucosal effects over one to four weeks; anaemia correction studies measured haemoglobin change at 30 days.
Routes
oral, topical, intranasal
Molecule
Iron-binding glycoprotein (single-chain, two-lobed)
Sequence length
689 amino acids
Molecular weight
80000 Da

Handling

Diluent
Not applicable
Lyophilised
Cool, dry, sealed. Refrigeration extends shelf life and is worth doing with powder.
Reconstituted
Not applicable.

Intranasal — usable, with a caveat

Nasal lactoferrin is used for a local effect on the nasal mucosa rather than for systemic absorption - antimicrobial and iron-sequestering activity where it is sprayed. It has been trialled in respiratory infection contexts. Do not expect nasal dosing to produce meaningful systemic levels; that is not what the route is for here.

Mixing

Sold as capsules or powder. Do not heat it - lactoferrin denatures readily, which is also why it should not be added to hot drinks.

Side effects

  • commonNausea or GI discomfort— Mostly at higher doses on an empty stomach.
  • uncommonConstipation— Related to its iron-handling effects.
  • rareSkin rash
  • rareDairy allergy reaction— Bovine lactoferrin is a milk protein - a true milk allergy can produce a serious reaction.

Do not use if

  • Cow's milk protein allergy.
  • Iron overload states such as haemochromatosis warrant caution because lactoferrin suppresses hepcidin and can increase iron absorption.

Combining it

  • cautionOral iron supplements — Lactoferrin improves iron absorption and status; combining them is sometimes intended but can push iron too high - separate them and check ferritin.
  • synergycolostrinin — Same source material and complementary mucosal immune effects.
  • synergyAntibiotics for H. pylori — Adjunct lactoferrin has improved eradication rates in several trials.
  • synergykpv — Frequently paired in gut protocols - lactoferrin on the luminal/antimicrobial side, KPV on the NF-kB inflammatory side.

What to monitor

  • · Ferritin and full iron studies if you are using it long term or have any iron-overload risk.
  • · Symptom tracking for gut protocols - stool consistency, bloating, infection frequency.

Legal status

Sold freely as a dietary supplement in the US, EU and most markets; GRAS-affirmed as a food ingredient in the US.

References

  • ELFIN: enteral lactoferrin supplementation in very preterm infants, randomised controlled trial (Lancet 2019) (trial)
  • Bovine lactoferrin as an adjunct in Helicobacter pylori eradication, meta-analysis (review)
  • Lactoferrin structure, iron binding and antimicrobial mechanism review (review)

Mechanism in depth

Four mechanisms operate in parallel and it is worth separating them because they respond to different things. First, iron sequestration: apo-lactoferrin's affinity for Fe3+ is roughly 300 times that of transferrin and it holds iron down to pH 3, which strips the metal from the environment siderophore-dependent bacteria depend on. This is a bacteriostatic mechanism and it is abolished if you take lactoferrin with iron - which is the practical reason for separating them. Second, direct membrane action: the cationic N-terminal region binds lipopolysaccharide and anionic bacterial membranes and permeabilises them, and pepsin liberation of lactoferricin concentrates this activity into a small potent fragment. This is bactericidal and it is not iron-dependent. Third, viral entry blockade: lactoferrin binds heparan sulfate proteoglycans on host cells, occupying the attachment sites several viruses use for initial docking. This is an in vitro finding that has repeatedly failed to translate cleanly into clinical endpoints - hold it loosely. Fourth, and probably the most clinically consequential in a healthy adult, iron regulation via hepcidin: Paesano's work established that lactoferrin reduces hepcidin and therefore relieves the ferroportin block on iron export from enterocytes and macrophages. That is why it corrects anaemia of inflammation and iron-deficiency anaemia in pregnancy, and it is the mechanism behind the single most reproducible clinical result the compound has. It is also why haemochromatosis is a genuine contraindication rather than a hedge - you are removing the body's brake on iron absorption. Immunologically it modulates TLR4 signalling and reduces NF-kB-driven cytokine output in inflamed mucosa, which is the basis for the gut protocols.

What usually goes wrong

The failure that actually harms people is iron. Lactoferrin suppresses hepcidin, hepcidin is the body's brake on iron absorption, and taking a hepcidin suppressor daily for years without ever checking ferritin is how someone with an undiagnosed HFE genotype loads iron quietly. Check transferrin saturation before you make this a permanent supplement. The second problem is expectation transfer: the in vitro antiviral and antimicrobial data are genuinely impressive and the clinical translation is genuinely poor - ELFIN randomised 2,203 preterm infants and found nothing. Do not let a mechanism paper set your expectations when a large trial exists. Third, the routine one: nausea and constipation, almost entirely from high doses on an empty stomach, fixed by splitting the dose or dropping back to 200 mg. Fourth, a true cow's milk protein allergy can produce a severe reaction - this is a milk protein, and 'it's a peptide supplement' is not a defence. Finally, product quality: iron saturation is rarely stated, heat treatment during manufacture denatures it, and a lactoferrin that has been through a hot spray-drying step is not doing what the label says.

Titration ladder

  1. 200 mgWeek 1 — 200 mg once daily. Nausea on lactoferrin is almost entirely a dose-and-empty-stomach phenomenon, and starting here avoids it. This is also where most of the human evidence sits.
  2. 200 mgWeeks 2-4 — 200 mg twice daily, morning and evening, away from food and away from any iron supplement. Splitting the dose is better tolerated than doubling a single one.
  3. 400 mgWeek 4 onward, only if the indication warrants it — 400 mg twice daily. This is the top of where trial evidence exists - the H. pylori adjunct protocols used roughly 200-400 mg twice daily. Above about 1 g a day you are buying gastrointestinal upset, not effect.

Bloodwork worth running

MarkerWhenWhy it matters
Ferritin, serum iron, total iron binding capacity and transferrin saturationBaseline, then at 8-12 weeks on continuous use. The pregnancy anaemia trials measured haemoglobin change at 30 days, so a 4-week check is reasonable if you are treating deficiency.This is the marker set that actually matters on lactoferrin, and the one nobody checks. The compound suppresses hepcidin and increases iron absorption - which is the therapeutic effect in anaemia and an unwanted effect in anyone with iron-loading risk.Act if: Transferrin saturation above 45 percent or ferritin rising above roughly 300 ng/mL in a man or 200 ng/mL in a woman means stop and investigate for haemochromatosis rather than continue. Conversely, if you are treating deficiency and ferritin has not moved at 12 weeks, oral lactoferrin is not the right tool for you.
Haemoglobin and full blood countBaseline and 30 days if treating anaemia.The efficacy endpoint in the strongest evidence base this compound has - iron-deficiency anaemia in pregnancy, where lactoferrin performed comparably to ferrous sulfate with substantially fewer gastrointestinal side effects.Act if: No haemoglobin response at 30 days means reassess the diagnosis - lactoferrin does not fix anaemia that is not iron-related.
hs-CRPAlongside every ferritin measurement.Relevant in two directions. It contextualises ferritin, which is an acute-phase reactant and rises with inflammation independent of iron stores. It also tracks the anaemia-of-inflammation mechanism, where hepcidin suppression is the point.Act if: A high CRP makes a normal ferritin uninterpretable - you may still be iron deficient.
Genetic haemochromatosis screening (HFE C282Y/H63D) if transferrin saturation is high at baselineOnce, if baseline transferrin saturation exceeds 45 percent or there is family history.Roughly one in two hundred people of Northern European descent are C282Y homozygotes, and for them a hepcidin suppressor taken daily for years is a genuinely bad idea.Act if: A confirmed loading genotype means do not take lactoferrin chronically.
H. pylori stool antigen or urea breath test, if that is the indicationFour weeks after completing eradication therapy, off proton pump inhibitors.The adjunct use has meta-analysed support for improved eradication rates and reduced side effects. It has a definite endpoint, so use it.Act if: A positive test after treatment means eradication failed regardless of what the adjunct did.

Pharmacokinetics

Crosses blood-brain barrier
no
Metabolism
Gastric pepsin cleavage yielding lactoferricin and lactoferrampin from the cationic N-terminal region, then progressive proteolysis by pancreatic and brush-border enzymes. Iron saturation state directly determines how fast this happens - holo-lactoferrin resists digestion considerably better than apo-lactoferrin.
Elimination
Faecal for the luminal fraction; hepatic receptor-mediated clearance for anything that reaches circulation.

Receptor targets

  • Fe3+ (two high-affinity binding sites, one per lobe) — Roughly 300-fold greater affinity than transferrin, and retains iron down to about pH 3 where transferrin releases it

    Sequesters free iron from the environment, denying it to siderophore-dependent bacteria. Bacteriostatic. Requires the apo form - saturated lactoferrin cannot do this.

  • Lipopolysaccharide and anionic bacterial membranes — Not quantified as a single constant - electrostatic interaction of the cationic N-terminal region

    Membrane permeabilisation and direct bactericidal killing, concentrated in the pepsin-liberated lactoferricin fragment. Independent of iron status.

  • Heparan sulfate proteoglycans on host cell surfaces — Not quantified

    Blocks the initial attachment step for several viruses in vitro including rotavirus and coronaviruses. In vitro evidence that has not reliably translated - the ELFIN result is the cautionary example.

  • Hepcidin (suppressed) and ferroportin (functionally relieved) — Not applicable - regulatory effect, not binding

    Lowers hepcidin, permitting ferroportin-mediated iron export from enterocytes and macrophages. This is the mechanism behind the iron-deficiency-anaemia results and the reason iron overload is a real contraindication.

  • TLR4 / NF-kB signalling in mucosal cells — Not quantified

    Dampens LPS-driven inflammatory cytokine output at the mucosal surface. The rationale for gut protocols.

  • Intestinal lactoferrin receptor (brush-border membrane) — Isolated and characterised by Kawakami in fetal intestinal brush-border membranes; adult expression and transport capacity are less well defined

    Receptor-mediated uptake of intact lactoferrin. Documented but quantitatively small.

Trials

  • ELFIN - Enteral Lactoferrin In Neonates Randomised placebo-controlled trial · n=2203 · 2019

    Bovine lactoferrin 150 mg/kg/day (maximum 300 mg/day) versus sucrose placebo in very preterm infants until 34 weeks postmenstrual age. Late-onset infection occurred in 316/1093 lactoferrin infants versus 334/1089 controls; risk ratio 0.95, p=0.233. A large, clean, negative result in 2,203 infants. This is the honest counterweight to every in vitro antimicrobial claim made for lactoferrin.

  • Nappi and colleagues, oral bovine lactoferrin versus ferrous sulfate in pregnant women with iron deficiency anaemia Prospective controlled randomised study · 2009

    Comparable efficacy to ferrous sulfate for correcting iron-deficiency anaemia in pregnancy with markedly better gastrointestinal tolerability. Participant number not confirmed from an accessible abstract and left null.

  • de Bortoli and colleagues, triple therapy versus triple therapy plus lactoferrin and probiotics for H. pylori eradication Randomised prospective study · 2007

    Improved eradication rate with lactoferrin and probiotic adjuncts added to standard triple therapy. One of the individual trials underlying the two 2009 meta-analyses.

What to expect, and when

Hours: luminal antimicrobial and iron-binding effects are immediate, because the drug is already where it works. Days 1-7: gastrointestinal tolerance settles or does not; nausea that persists past a week means the dose is wrong. Weeks 1-4: gut symptom changes - stool consistency, bloating - are the first thing most people notice, and the H. pylori adjunct trials ran over standard 7-14 day eradication courses. Day 30: the anaemia trials measured haemoglobin change here. This is the first hard endpoint. Weeks 8-12: ferritin and full iron studies become meaningfully interpretable. Months 3+: safe to continue, but this is the point at which iron monitoring stops being optional.

Stacking and comparisons

The most important pairing rule is a separation rule: keep lactoferrin away from oral iron by at least two hours. The apo form is what has antimicrobial activity, and taking it with iron saturates it and turns it into an ordinary protein. Ironically the two are often prescribed together because both raise haemoglobin - if you do that deliberately, check ferritin, because the combination of a hepcidin suppressor and an iron load can push iron higher than intended. With KPV the pairing is genuinely complementary in gut protocols: lactoferrin acting on the luminal, iron and TLR4 side, KPV on the intracellular NF-kB side. With colostrinin, check the label - both come from colostrum and the same raw material often contains both. As an H. pylori eradication adjunct alongside standard triple therapy, this is the one stack in the entire class with two independent meta-analyses behind it. Avoid taking it in hot drinks; the protein denatures and you have paid for whey powder.

Lactoferrin is the most evidence-backed non-prescription compound in this class by a wide margin - multiple randomised trials, two meta-analyses in H. pylori eradication, a meta-analysis in pregnancy anaemia, and a 2,203-patient negative trial that tells you where the limits are. That combination of positive and negative high-quality data is rarer than it should be in this field and it is what makes the compound trustworthy: you know what it does not do. Against colostrinin, from the same source material, lactoferrin has more indications and a clearer mechanism. Against the injectable thymic peptides it is a completely different proposition - oral, cheap, locally acting, and aimed at mucosal and iron biology rather than T-cell maturation. If your goal is gut and mucosal immunity, this is the first thing to try. If your goal is systemic immune restoration, it is the wrong tool and no dose of it will become the right one.

Rough cost

$15–$60/month. Ordinary supplement-market pricing for 200-400 mg daily. Capsules are cheaper than powder per gram in most cases. At the high end you are dosing 800 mg or more daily, which is above where most of the human evidence sits.

Genuinely uncertain

  • Systemic bioavailability after oral dosing has not been quantified in adults. It is known to be low; how low is not established.
  • The one-letter sequence is not reproduced here because bovine lactoferrin is 689 residues; the sequence is genuinely known and available from UniProt but was not transcribed or verified residue by residue in this session, so the sequence verified flag is false.
  • Iron saturation of commercial product is rarely disclosed and materially changes the pharmacology. Apo-lactoferrin is the antimicrobial form; most products do not say which they are.
  • Participant numbers and durations for the Nappi 2009 and de Bortoli 2007 trials were not confirmed from accessible abstracts and are left null.
  • The gap between strong in vitro antiviral data and the negative ELFIN outcome has not been satisfactorily explained. Whether it is a dose, formulation, population or mechanism problem is unresolved.
  • The optimal dose for gut and immune indications outside anaemia and H. pylori has never been established. The 200-400 mg range is where trials happened to sit, not a derived optimum.
  • Whether long-term daily use in an iron-replete adult carries any cumulative risk beyond iron loading has not been studied.

Papers